MIRA Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRA research report →
Price Chart
About the company
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog.
- CEO
- Erez Aminov
- IPO
- 2023
- Employees
- 2
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on MIRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.23M
- P/E
- -0.57
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 4.07
- EV/EBITDA
- -3.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -106.96%
- ROIC
- -115.18%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-10,493,112
- Net Income
- $-10,442,485-33.0%
- EPS
- $-1.35-164.7%
- OCF Growth
- +16.2%
- FCF Growth
- +16.2%
- 52W High
- $2.45
- 52W Low
- $0.60
- 50D MA
- $0.83
- 200D MA
- $1.11
- Beta
- 1.53
- RSI (14)
- 50
- Avg Volume
- 570.22K
No earnings-call transcripts are available for MIRA yet.
- Free Float
- 63.9%
- Shares Outstanding
- 42.02M
- Float Shares
- 26.86M
of shares held by institutions
26 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 751.80K | ▲ 57.89K |
| Vanguard Group Inc | 660.50K | ▲ 456.85K |
| Cross Staff Investments Inc | 359.40K | 0 |
| Geode Capital Management, LLC | 303.88K | ▲ 12.99K |
| Blackrock, Inc. | 244.62K | ▲ 132.28K |
| Vanguard Fiduciary Trust Co | 170.67K | ▲ 1.19K |
| Captrust Financial Advisors | 90.64K | ▲ 90.64K |
| Northern Trust Corp | 67.73K | ▲ 37 |
| First American Bank | 60.00K | 0 |
| Commonwealth Equity Services, LLC | 53.19K | ▲ 18.12K |
| State Street Corp | 49.10K | 0 |
| International Assets Investment Management, LLC | 35.00K | 0 |
Held by 24 ETFs
Biggest fund positions in MIRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | Whalen Matthew Pratt | other | 50,000 |
| Jun 12, 26 | Del Giudice Matthew Paul | other | 50,000 |
| Jun 12, 26 | MacPherson Edward Clouston | other | 50,000 |
| Jun 12, 26 | Shekhat Denil Nanji | other | 50,000 |
| Jun 2, 26 | Mushak Andriy | other | 0 |
| Mar 30, 26 | Aminov Erez | other | 83,500 |
| Dec 17, 25 | Aminov Erez | other | 3,155,170 |
| Oct 16, 25 | Aminov Erez | other | 379,000 |
| Oct 16, 25 | Aminov Erez | other | 234,595 |
| Oct 1, 25 | Shekhat Denil Nanji | other | 22,378 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MIRA coverage
Recent articles, reports, and earnings notes.
No research on MIRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MIRA report →Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, Mexico
newsfilecorp.com · Sep 3
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
globenewswire.com · Sep 1
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
globenewswire.com · Aug 6
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
globenewswire.com · Jul 30
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
accessnewswire.com · Jul 10
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
accessnewswire.com · Jul 6
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
accessnewswire.com · Jun 25
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
accessnewswire.com · Jun 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.